Design and construction a novel humanized biparatopic nanobody-based immunotoxin against epidermal growth factor receptor (EGFR)

[1]  Bahman Akbari,et al.  Paper Title “Hu7CG2: A Novel Humanized Anti-Epidermal Growth Factor Receptor (EGFR) Biparatopic Nanobody” , 2021, Molecular Biotechnology.

[2]  F. Safari,et al.  Immunotoxins and nanobody-based immunotoxins: review and update , 2021, Journal of drug targeting.

[3]  F. Safari,et al.  EGFR and anti-EGFR nanobodies: review and update , 2020, Journal of drug targeting.

[4]  Q. Jin,et al.  Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain , 2020, Nature Communications.

[5]  Zhangyong Hong,et al.  HER2-specific immunotoxins constructed based on single-domain antibodies and the improved toxin PE24X7. , 2019, International journal of pharmaceutics.

[6]  K. Goldberg,et al.  FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm , 2019, Clinical Cancer Research.

[7]  G. Ciofani,et al.  Innovative approaches for cancer treatment: current perspectives and new challenges , 2019, Ecancermedicalscience.

[8]  Biyan Wen,et al.  Preparation and characterization of humanized nanobodies targeting the dimer interface of epidermal growth factor receptor (EGFR). , 2019, Protein expression and purification.

[9]  V. Schirrmacher.  From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review) , 2018, International journal of oncology.

[10]  S. Farajnia,et al.  Expression and Evaluation of HuscFv Antibody -PE40 Immunotoxin for Target Therapy of EGFR-Overexpressing Cancers , 2018, Iranian journal of biotechnology.

[11]  S. Farajnia,et al.  Soluble Expression of Humanized Anti-CD20 Single Chain Antibody in Escherichia coli by Cytoplasmic Chaperones Co-expression , 2018, Avicenna journal of medical biotechnology.

[12]  J. van Rheenen,et al.  Potential impact of invasive surgical procedures on primary tumor growth and metastasis , 2018, Clinical & Experimental Metastasis.

[13]  S. Muyldermans,et al.  Design of a humanized anti vascular endothelial growth factor nanobody and evaluation of its in vitro function , 2018, Iranian journal of basic medical sciences.

[14]  Jiayu Liu,et al.  Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells , 2018, PloS one.

[15]  S. Sigismund,et al.  Emerging functions of the EGFR in cancer , 2017, Molecular oncology.

[16]  Shuifa Wu,et al.  Novel recombinant immunotoxin of EGFR specific nanobody fused with cucurmosin, construction and antitumor efficiency in vitro , 2017, Oncotarget.

[17]  F. Tian,et al.  Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential , 2017, International journal of nanomedicine.

[18]  A. Barzegar,et al.  Construction, expression, and activity of a novel immunotoxin comprising a humanized antiepidermal growth factor receptor scFv and modified Pseudomonas aeruginosa exotoxin A , 2017, Anti-cancer drugs.

[19]  K. Ginalski,et al.  Towards Engineering Novel PE-Based Immunotoxins by Targeting Them to the Nucleus , 2016, Toxins.

[20]  S. Farajnia,et al.  Invert biopanning: A novel method for efficient and rapid isolation of scFvs by phage display technology. , 2016, Biologicals : journal of the International Association of Biological Standardization.

[21]  S. Farajnia,et al.  Design, expression and evaluation of a novel humanized single chain antibody against epidermal growth factor receptor (EGFR). , 2016, Protein expression and purification.

[22]  S. Farajnia,et al.  Development and evaluation of a single domain antibody against human epidermal growth factor receptor (EGFR). , 2016, Protein expression and purification.

[23]  I. Pastan,et al.  Immunogenicity of therapeutic recombinant immunotoxins , 2016, Immunological reviews.

[24]  H. Hartung,et al.  Pseudomonas aeruginosa and Its Bacterial Components Influence the Cytokine Response in Thymocytes and Splenocytes , 2016, Infection and Immunity.

[25]  I. Pastan,et al.  Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo , 2015, Cellular and Molecular Immunology.

[26]  I. Pastan,et al.  New Life for Immunotoxin Cancer Therapy , 2015, Clinical Cancer Research.

[27]  D. Baker,et al.  Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes , 2014, Proceedings of the National Academy of Sciences.

[28]  H. Stephan,et al.  High-yield production of functional soluble single-domain antibodies in the cytoplasm of Escherichia coli , 2013, Microbial Cell Factories.

[29]  Serge Muyldermans,et al.  Nanobodies: natural single-domain antibodies. , 2013, Annual review of biochemistry.

[30]  K. Borden,et al.  Mechanisms and insights into drug resistance in cancer , 2013, Front. Pharmacol..

[31]  R. Verma,et al.  Therapeutic targets and recent advances in protein immunotoxins. , 2012, Current opinion in microbiology.

[32]  I. Pastan,et al.  A guide to taming a toxin – recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer , 2011, The FEBS journal.

[33]  A. Verkleij,et al.  A biparatopic anti‐EGFR nanobody efficiently inhibits solid tumour growth , 2011, International journal of cancer.

[34]  I. Pastan,et al.  A Recombinant Immunotoxin Targeting CD22 With Low Immunogenicity, Low Nonspecific Toxicity, and High Antitumor Activity in Mice , 2010, Journal of immunotherapy.

[35]  M. Jaramillo,et al.  Differential tumor-targeting abilities of three single-domain antibody formats. , 2010, Cancer letters.

[36]  B. Beaumelle,et al.  Processing of Pseudomonas aeruginosa Exotoxin A Is Dispensable for Cell Intoxication , 2009, Infection and Immunity.

[37]  I. Pastan,et al.  A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. , 2009, Blood.

[38]  S. Muyldermans,et al.  General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold* , 2009, Journal of Biological Chemistry.

[39]  Christian Vanhove,et al.  Comparison of the Biodistribution and Tumor Targeting of Two 99mTc-Labeled Anti-EGFR Nanobodies in Mice, Using Pinhole SPECT/Micro-CT , 2008, Journal of Nuclear Medicine.

[40]  I. Pastan,et al.  Immunotoxin treatment of cancer. , 2007, Annual review of medicine.

[41]  R. Kreitman,et al.  Immunotoxins for targeted cancer therapy , 2006, The AAPS Journal.

[42]  D. Bigner,et al.  Monoclonal antibodies for brain tumour treatment , 2004, Expert opinion on biological therapy.

[43]  A. Sandler,et al.  Epidermal growth factor receptor: a promising target in solid tumours. , 2004, Cancer treatment reviews.

[44]  A. Plückthun,et al.  A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  S. You,et al.  Construction and high-level expression of a single-chain Fv antibody fragment specific for acidic isoferritin in Escherichia coli. , 2003, Journal of biotechnology.

[46]  N. Hynes,et al.  The ErbB receptors and their role in cancer progression. , 2003, Experimental cell research.

[47]  P. Koehl,et al.  Refined crystallographic structure of Pseudomonas aeruginosa exotoxin A and its implications for the molecular mechanism of toxicity. , 2001, Journal of molecular biology.

[48]  V. Ghetie,et al.  Chemical construction of immunotoxins , 2001, Molecular biotechnology.

[49]  M. Mizuno,et al.  Production of a Single‐chain Variable Fragment Antibody Recognizing Type III Mutant Epidermal Growth Factor Receptor , 2000, Japanese journal of cancer research : Gann.

[50]  S. Muyldermans,et al.  Unique single‐domain antigen binding fragments derived from naturally occurring camel heavy‐chain antibodies , 1999, Journal of molecular recognition : JMR.

[51]  R. Kreitman,et al.  An early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor. , 1997, Biochemistry.

[52]  I. Pastan,et al.  Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. , 1995, The Biochemical journal.

[53]  S. Muyldermans,et al.  Naturally occurring antibodies devoid of light chains , 1993, Nature.

[54]  D. Buchsbaum,et al.  Chapter seven--Cancer treatment with gene therapy and radiation therapy. , 2012, Advances in cancer research.